SOURCE: The Bedford Report

The Bedford Report

August 09, 2011 08:16 ET

BioSante and Discovery Labs Benefit From New Industry Trends

The Bedford Report Provides Equity Research on BioSante Pharmaceuticals & Discovery Laboratories

NEW YORK, NY--(Marketwire - Aug 9, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation, and discoveries continue to elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Discovery Laboratories, Inc. (NASDAQ: DSCO). Access to the full company reports can be found at:

www.bedfordreport.com/BPAX

www.bedfordreport.com/DSCO

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill its pipeline, which has been a net positive for small biotech companies.

According to Thomson Reuters, on average biotech companies in the NASDAQ Biotechnology Index (NBI) spent $54 million on R&D in 2010, reflecting a 7 percent decline from 2009.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

BioSante is currently running three late-stage clinical trials of LibiGel, a female sexual dysfunction treatment. The company plans to file a new marketing application in early 2012. In June, BioSante said it had stopped enrolling patients in a safety trial because a data analysis indicated a 90-percent chance the drug would meet its goal.

Discovery Laboratories is a specialty biotechnology company dedicated to improving the standard of respiratory critical care through its KL4 surfactant and aerosol drug delivery technologies. W. Thomas Amick, Chairman of the Board and Chief Executive Officer, says that the company's product candidates AFECTAIR and SURFAXIN could potentially be arriving on the market in 2012.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information